Alivus Life Sciences Ltd.

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capita land Disclosure Requirements) Regulations, 2018, Glenmark Life Sciences has informed that it enclosed Monitoring Agency Report issued by HDFC Bank, Monitoring Agency, for the quarter ended 30th June, 2022 in respect of utilization of proceeds of the IPO of the Company.

The above information is a part of company’s filings submitted to BSE.